Visfatin, predominantly secreted by visceral adipose tissue, exhibits insulin-mimetic activity but is paradoxically increased in metabolic syndrome, diabetic microangiopathy and insulin-resistant states, reflecting both compensatory and pathogenic mechanisms as indicated in clinical observational studies and mechanistic evidence [43,44,45]. The gene discussed is INS; the disease is metabolic syndrome.